Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia

Bone Marrow Transplantation

Volumn 41, Issue 1, 2008, Pages 69-78

  Bitan, M ^a   Or, R ^a   Shapira, M Y ^a   Resnick, I B ^a   Gesundheit, B ^a   Ackerstein, A ^a   Samuel, S ^a   Elad, S ^b   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMIKACIN; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; BUSULFAN; CEFAZOLIN; CEFTAZIDIME; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; GENTAMICIN; MELPHALAN; MEROPENEM; METHYLPREDNISOLONE; MEZLOCILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; THIOTEPA; THYMOCYTE ANTIBODY; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; ENGRAFTMENT; FEMALE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HUMAN; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PANCYTOPENIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 38349068471     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705878     Document Type: Article

References (32)

1. Aizawa S, Nakano M, Yaguchi M, Kuriyama Y, Iwasa O, Toyama K et al Possible involvement of bone marrow stromal cells in agranulocytosis caused by vesnarinone treatment. Acta Haematol 1997; 98: 140-146.
2. Koeffler HP. Myelodysplastic syndrome (preleukemia). Semin Haematol 1986; 23: 284-299.
3. Janssen JW, Buschle M, Layton M, Drexler HG, Lyons J, van den Berghe H et al. Clonal analysis of myelodysplastic syndromes: Evidence of a multipotent stem cell origin. Blood 1984, 73: 248-254.
4. Greenberg PL. The smoldering myeloid leukemia states: Clinical and biological features. Blood 1983; 61: 1035-1044.
5. Clark BR, Keating A. Biology of bone marrow stroma. Ann New York Acad Sci 1995; 770: 70-78.
6. Raza A, Yousuf N, Bokhari SA, Sheikh Y, Akhtar S, Chughtai S et al. In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies, Leuk Res 1992; 16: 299-306.
7. Mecucci C. Molecular features of primary MDS with cytogenetic changes. Leuk Res 1998; 22: 293-302.
8. Willman CL. Molecular genetic features of myelodysplastic syndromes (MDS). Leukemia 1998; 12: 2-6.
9. Raza A. Mundle S, Iftikhar A, Gregory S, Marcus B, Khan Z et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 1995; 48: 143-154.
10. Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999; 23 239-246.
11. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
12. Novitzky N, Mohamed R, Finlayson J, du Toit C. Increased apoptosis of bone marrow cells and preserved proliferition capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes. Exp Hematol 2000; 28: 941-949.
13. Tauro S, Hepburn MD, Bowen DT, Pippard MJ. Assessment of stromal function and its potential contribution to deregulation of hematopoiesis in the myclodysplastic syndromes. Haematologica 2001; 86: 1038-1045.
14. Spyridonidis A, Kuttler T, Wasch R, Samek E, Waterhouse M, Behringer D et al. Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin. Stem Cells Dev 2005; 14 213-222.
15. Weber-Mzell D, Urban C, Benesch M, Rojacher T, Zois B, Hofler G et al Durable remission following a third allogeneic stem cell transplantation in a patient with repeatedly relapsing SAA. The importance of stroma cells for sustained engraftment? Pediatr Transplant 2007; 11: 332-335.
16. Schmid C, Schleuning; M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
17. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 2006, 20: 128-135.
18. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-328.
19. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-ceil transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
20. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablatiye, reduced-toxicity conditioning regimen for allogeneic item cell transplantation in AML and MDS. Blood 2004; 104, 857-864.
21. Garderet L, Labopin M, Gorin NC, Polge E, Baruchel A, Meloni G et al Hematopoietic stem-cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2OO5; 105: 405-409.
22. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444-453.
23. Mori T, Aisa Y, Yokoyama A, Nakazato T, Yamazaki R, Shimizu T et al Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: A single-institute experience. Bone Marrow Transplant 2007; 39: 217-221.
24. Sierra J, Pe'rez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
25. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PF, Lerner KG et al. Clinical manifestations of graft-versus-host disease in human recipient of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
26. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM et al Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 247-254.
27. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273-275.
28. Nakamura Y, Leppert O, O'Connel P, Wolff R, Holm T, Culver M et al Variable number of tandem repeats (VNTR) markets for human gene mapping. Science 1987; 235: 1616-1622.
29. Stem cell Trailists' Collaborative Group. Allogeneic peripheral blood stem cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trails. J Clin Oncol 2005; 23: 5074-5087.
30. Zweegman S, Kessler FL, Kerkhoven RM, Heimerikx M, Celie Jw, Janssen JJ et al. Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile. Matrix Biol 2007; e-pub ahead of print, 19 April 2007.
31. Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stern cell transplantation. Transpl Infect Dis 2004; 6: 171-178.
32. Gurevitch O, Kurkalli BG, Prigozhina T, Kasir J, Gaft A, Slavin S. Reconstruction of cartilage, bone, and hematopoietic microenvironment with demineralized bone matrix and bone marrow cells. Stem Cells 2003; 21: 588-597.